金吾财讯 | 英派药业-B（07630）股价走高，曾一度升逾20%，随后涨幅回落，最新报13.34港元，涨3.41%，成交额1.36亿港元。
消息面上，公司H股已获纳入沪港通及深港通合资格证券名单，并自2026年9月7日起生效。
根据此前英派药业公布的截至2026年6月30日止六个月中期业绩，期内收入达1.05亿元人民币，较去年同期的2520万元人民币大幅增长316.8%，主要来自核心产品塞纳帕利在中国的销售收入7040万元人民币（YoY增长877.8%）及与Eikon Therapeutics合作协议的里程碑付款3480万元人民币。毛利率为90.8%。期内亏损9080万元人民币，较去年同期的1.29亿元人民币收窄29.5%；经调整亏损净额（非香港财务报告准则计量）为2090万元人民币，较去年同期的5580万元人民币大幅减少62.6%。研发开支为9760万元人民币（YoY增长13.1%），主要用于塞纳帕利的欧洲药品管理局审查及早期候选药物的临床前研发。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.